- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Guardant Health Inc (GH)
NASDAQ
Symbol | Exchange | Currency |
|---|
50.36
-1.06(-2.06%)
After Hours
51.67
+1.31(+2.60%)
- Real-time Data
- Volume:726,032
- Day's Range:48.71 - 51.34
- 52 wk Range:27.65 - 133.82
GH Overview
- Prev. Close
- 51.42
- Day's Range
- 48.71-51.34
- Revenue
- 408.13M
- Open
- 51.34
- 52 wk Range
- 27.65-133.82
- EPS
- -5.42
- Volume
- 726,032
- Market Cap
- 5.15B
- Dividend (Yield)
- N/A(N/A)
- Average Vol. (3m)
- 1,170,741
- P/E Ratio
- -9.81
- Beta
- 0.799
- 1-Year Change
- -49.09%
- Shares Outstanding
- 102,220,389
- Next Earnings Date
- Nov 03, 2022
What is your sentiment on Guardant Health?
or
Market is currently closed. Voting is open during market hours.
Guardant Health Inc News
- Guardant Health Tops Q2 EPS by 21c
- ByInvesting.com-
Guardant Health (NASDAQ:GH) reported Q2 EPS of ($1.00), $0.21 better than the analyst estimate of ($1.21). Revenue for the quarter came in at $109.1 million versus the consensus...
- Leerink Partners Stick to Their Buy Rating for Guardant Health
- ByInvesting.com-
Leerink Partners analyst Puneet Souda maintained a Buy rating on Guardant Health (NASDAQ:GH) on Tuesday, setting a price target of $180, which is approximately 42.33% above the...
Guardant Health Inc Analysis
- Mixed Session as Fed, Earnings Compete For Market’s Attention
We’re in the thick of big tech earnings right now and also had to deal with a Fed statement on Wednesday, so it’s no surprise that today’s session saw an...
- Bull of the Day: Exact Sciences (EXAS)
Exact Sciences (NASDAQ:EXAS) EXAS is the $19 billion leader in proactive cancer diagnostics with the Cologuard screening kit, which the majority of healthcare providers are...
- Dow Jumps Nearly 1.5% to Reach a New Closing High
SPECIAL ALERT: Remember, the March episode of the Zacks Ultimate Strategy Session is now available for viewing! Don’t miss your chance to hear: ▪ Jeremy Mullin and Brian...
Guardant Health Inc Company Profile
Guardant Health Inc Company Profile
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
Read More
Technical Summary
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Neutral | Sell | Sell | Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Sell | Neutral | Strong Sell |
| Summary | Strong Buy | Buy | Strong Sell | Neutral | Strong Sell |
Trending Stocks
Trending Stocks
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 48.58 | 49.52 | 48.38 | -0.69 | -1.40% | 18.48M | NYSE | |||
| 166.77 | 168.30 | 165.93 | -0.81 | -0.48% | 8.30M | NYSE | |||
| 120.86 | 121.68 | 119.56 | +0.54 | +0.45% | 15.38M | NASDAQ | |||
| 18.55 | 20.81 | 16.16 | -4.53 | -19.63% | 136.95M | NASDAQ | |||
| 55.99 | 56.08 | 55.90 | 0.00 | 0.00% | 0.00 | NASDAQ | |||
| 26.30 | 26.38 | 25.86 | +0.18 | +0.69% | 158.88K | NYSE | |||
| 75.25 | 75.28 | 74.28 | +0.51 | +0.68% | 307.16K | NASDAQ | |||
| 7.66 | 7.72 | 7.63 | +0.03 | +0.39% | 4.19M | NASDAQ | |||
| 439.35 | 444.58 | 436.87 | -2.24 | -0.51% | 851.29K | NYSE | |||
| 100.44 | 101.07 | 96.73 | +2.17 | +2.21% | 75.87M | NASDAQ | |||
| 0.97 | 0.98 | 0.92 | +0.03 | +2.67% | 42.62K | NASDAQ | |||
| 150.00 | 158.51 | 148.26 | -8.00 | -5.06% | 6.91M | NASDAQ | |||
| 51.46 | 51.93 | 48.42 | +3.62 | +7.57% | 6.15M | NYSE | |||
| 90.68 | 91.88 | 88.52 | +0.91 | +1.01% | 13.01M | NYSE | |||
| 0.65 | 0.66 | 0.61 | +0.02 | +3.05% | 6.29M | NYSE |
- Mar 22, 2022, 16:59Number one player in the liquid biopsy, but macro enviroment is likely dragging down the price further..?!
- Nov 25, 2021, 11:02no divided shares
- Nov 05, 2021, 18:22GH has all the right elements to be a $180 stock with a year in a hot segment
- Sep 15, 2020, 09:06I am so imptient to see Q3 figures with FDA approval on blood test and covid test 🚀🚀
- Sep 14, 2020, 23:35doing well...
- Mar 13, 2020, 04:46one of the only stocks to actually have gains......I missed my chance
- Feb 25, 2020, 19:46I was right, inept people are written reccomendations for money given by such sh... company like GH.
- Sep 16, 2019, 23:59I followed zacks.com reccommendations but simply; worth for nothing (so many others)!
- Sep 16, 2019, 22:08Hope GH will fall to 30 lol
- Sep 12, 2019, 11:47this is a tremendous company: it was though impossible to buy at the levels it reached: now it is starting to have some serious upside.